Previous studies have demonstrated that RCC is more often associated with high microsatellite instability (MSI-H) and KRAS and BRAF mutations than LCC.9 Because of the worse prognosis of RCC, there is an urgent need to screen and identify RCC-specific tumor biomarkers for prognosis prediction and to guide the development of potential anticancer therapy. This evidence concerns the gene KRAS and renal cell carcinoma.